Roth Capital Initiates Ohr Pharmaceutical With Buy

Analysts at Roth Capital initiated coverage on

with a Buy rating. The target price for Ohr Pharmaceutical is set to $30. Ohr Pharmaceutical shares have dropped 51.72% over the past 52 weeks, while the S&P 500 index has surged 14.00% in the same period. Ohr Pharmaceutical's shares fell 0.57% to close at $7.02 yesterday.